Neptune Generics v. Eli Lilly & Company, Case No. 2018-1257, 2018-1258 (Fed. Cir. April, 2019), concerns an Eli Lilly & Co. patent protecting method of administering folic acid and a methylmalonic acid (MMA) lowering agent, e.g., vitamin B12. Specifically, the method concerns the administration of these products before administering pemetrexed disodium, an anti-folate chemotherapeutic, to reduce toxic effects of the anti-folate.
Latest Post
More Posts
Have You Included Specific Reference to Every Document in Your Priority Claim?
Federal Circuit Affirms Tribal Sovereign Immunity Does Not Apply to IPR
Tribal Sovereign Immunity Alone Cannot Protect Patents from IPR
Precedential and Informative Board Decision on Serial IPR Petitions
Late Payment of Petition Fee Thwarts IPR
IPR Challenge May Proceed Even in the Absence of Some Patent Owners
Presentation Not Qualified as a Printed Publication Because Audience Lacked Expertise
PTAB Declines to Institute IPR on Immersion’s Indefinite Means Plus Function Claims
PTAB Should Have Canceled All Challenged Claims in CBM Reviews
Subscribe: Subscribe via RSS
Blogs
Firm/Org